

Catalog# BP-50200

Gemtuzumab ozogamicin

Description:

Gemtuzumab ozogamicin is an antibody-drug conjugate (ADC) composed of the CD33-directed monoclonal antibody (hP67.6; recombinant humanized immunoglobulin [Ig] G4, kappa antibody produced by mammalian cell culture in NS0 cells) that is covalently linked to the cytotoxic agent N-acetyl gamma calicheamicin. Gemtuzumab ozogamicin consists of conjugated and unconjugated gemtuzumab. The conjugated molecules differ in the number of activated calicheamicin derivative moieties attached to gemtuzumab. The number of conjugated calicheamicin derivatives per gemtuzumab molecule ranges from predominantly zero to 6, with an average of 2 to 3 moles of calicheamicin derivative per mole of gemtuzumab. This product is for research use only. Gemtuzumab ozogamicin has the following structure:



Product Details	
CAS No.	220578-59-6
Species Reactivity	Human
Туре	Antibody-drug conjugate
ADC antibody	Gemtuzumab (Anti-CD33)
Target	Human CD33
ADC cytotoxin (drug)	Calicheamicin
Purity	98%
DAR	~2-3
Molecular Weight	N/A
Formulation	Lyophilized solid
Purification	Size exclusive column
Storage conditions	-80°C, protect from light.